Genetic testing is highly recommended before carbamazepine is administered to patients from China, due to high risk for carrying HLA-B*1502. Patients carrying HLA-B*1502 are at strongly increased risk for life treatening carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Prevalence of  HLA-B*1502 is high in several Asian countries, including China.
The first report stated (Han-Chinese living in Taiwan): The odds ratio if positive for HLA-B*1502 for developing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis was 2504 (95% CI: 126−49,522) (Ferrel, 2008). Later a systematic review yielded a summary odds ratio of 115.32; (95% CI, 18.17-732.13) among Han-Chinese. (Tangamornsuksan et al., 2013).

See also: Special topics.

Pharmacokinetics China

Toxicity
Patients carrying HLA-B*1502 are at strongly increased risk for life treatening carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). See: special topics.
Liberation
 
Administration/absorption
 
Distribution
 
Metabolism

 

CYP1A2

There are no major interethnic differences in the expression of CYP1A2-related activity between Caucasians and Chinese, although Chinese women as a subgroup may exhibit comparatively lower enzyme activity (Bartoli, 1996).


CYP3A

 


CYP2B6

 


CYP2C8

 


CYP2C9

 


CYP2C19

 


CYP2D6

 
Excretion